1.

ŠVAJGER U, OBERMAJER N, JERAS M. Tolegenic dendritic cells prepared with high concentration s of interferon-gamma.

We have developed and patent-protected a new protocol for preparation of tolerogenic DCs with particular properties, using high amounts of interferon-gamma. These cells represent a potential tool for preparing therapeutic cellular drugs - regulatory T lymphocytes that could be used for treatment of different immune diseses.

F.33 Slovenian patent

2.

ŠVAJGER U, ANDERLUH M, JERAS M. A method for determination of intrinsic activity of DC-SIGN receptor inhibitors.

The proposed invention represents a new protocol for the assessment of agonism or antagonism of the existing and new synthetic inhibitors of the DC-SIGN lectin receptor expressed on dendritic cells (DCs). The assessment of the intrinsic activity of DC-SIGN inhibitors is based on the determination of cytokine profiles of DCs, being concomitantly exposed or unexposed to TLR agonists.

F.33 Slovenian patent

3.

JERAS M. Advanced cell-based therapies. 4th BBBB-Bled International Conference on Pharmaceutical Sciences. New Trends in Drug Discovery, Delivery Systems and Laboratory Diagnostics. 29th September – 1st October, 2011, Bled, Slovenia. Keynote Lecture

The invited speaker has presented the achievements of the project research group in the field of dendritic cell-based cellular preparations as potential therapeutics for cancer and other immune-based diseases.

B.04 Guest lecture